1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GSK plc
  6. News
  7. Summary
    GSK   GB00BN7SWP63

GSK PLC

(GSK)
  Report
Delayed London Stock Exchange  -  11:35 2022-08-16 am EDT
1425.00 GBX   +1.35%
02:34pGSK says plaintiffs seeks voluntary dismissal of first Zantac lawsuit
RE
02:04pGSK Says Will Continue To Vigorously Defend Itself Against All Claims Alleging Cancer Risk Associated With The Use Of Ranitidine
RE
02:04pGsk - gsk will continue to vigorously defend itself against all…
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GSK Completes $1.9 Billion Purchase of Sierra Oncology

07/01/2022 | 10:48am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
GSK PLC 1.35% 1425 Delayed Quote.-14.46%
All news about GSK PLC
02:34pGSK says plaintiffs seeks voluntary dismissal of first Zantac lawsuit
RE
02:04pGSK Says Will Continue To Vigorously Defend Itself Against All Claims Alleging Cancer R..
RE
02:04pGsk - gsk will continue to vigorously defend itself against all…
RE
02:04pGsk - gsk did not settle bayer’s claim and has not paid anything…
RE
02:04pSTATEMENT : Zantac (ranitidine) U.S. litigation
PU
02:03pGsk -notice of voluntary dismissal to be filed in bayer case, fi…
RE
02:03pGSK-STATEMENT : Zantac (ranitidine) u.s. litigation…
RE
09:05aAstraZeneca Sues Former Executive to Prevent Potential Therapy Data Leak to Rival GSK
MT
06:43aGSK Closes Purchase of Affinivax
MT
06:34aGLAXOSMITHKLINE : GSK completes acquisition of Affinivax, Inc - Form 6-K
PU
More news
Analyst Recommendations on GSK PLC
More recommendations
Financials
Sales 2022 29 306 M 35 460 M 35 460 M
Net income 2022 4 411 M 5 337 M 5 337 M
Net Debt 2022 14 842 M 17 959 M 17 959 M
P/E ratio 2022 13,2x
Yield 2022 4,27%
Capitalization 57 688 M 69 803 M 69 803 M
EV / Sales 2022 2,47x
EV / Sales 2023 2,30x
Nbr of Employees 90 096
Free-Float 93,6%
Chart GSK PLC
Duration : Period :
GSK plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GSK PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 1 406,00 GBX
Average target price 2 038,46 GBX
Spread / Average Target 45,0%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Jon Ellis VP & Head-Technology Business Development
Tony Wood Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GSK PLC-14.46%68 741
JOHNSON & JOHNSON-2.91%436 680
ELI LILLY AND COMPANY13.66%298 298
PFIZER, INC.-15.75%279 215
ROCHE HOLDING AG-16.14%277 502
ABBVIE INC.5.09%251 582